Read our latest updates & insights

Alvotech announces completion of enrolment in Phase III trials of biosimilar adalimumab AVT02.  407 participants across Europe have enrolled, while Phase I PK trials are ongoing.

Celltrion announces start of Phase I Clinical trials of omalizumab biosimilar, with Phase III trials expected to begin in the first half of 2020.

We previously reported that Samsung Bioepis commenced proceedings in July 2019 in the AU Federal Court seeking to revoke an adalimumab formulation and use patent owned by Fresenius Kabi.  In an interesting development, Fresenius Kabi surrendered the patent in the patent off...

Study finds mAbxienxe’s biosimilar rituximab candidate RTXM83 is not inferior to the reference drug in terms of efficacy.

Mylan launches Hulio® in Spain following EC approval in September 2018.

Catalyst Biosciences announce eptacog alfa biosimilar met primary endpoints in Ph II trials.

A new study reveals rituximab may be effective in managing mixed cryoglobulinemic vasculitis.

Samsung and Genentech settle patent dispute, allowing for the sale of Samsung’s Ontruzant®.

Prestige announces agreements with Pharmapark and Mundipharma for the supply and commercialisation of Tuznue® . An agreement reached with Pharmapark allows for supply and commercialisation in Russia, while the agreement with Mundipharma grants an exclusive license and suppl...

Amgen withdraws its Marketing Authorisation application for biosimilar infliximab ABP710, citing a change in product strategy.